This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
clinical trials | 553 |
clinical trial | 264 |
adverse events | 131 |
clinical research | 125 |
controlled trial | 102 |
acute respiratory | 99 |
standard care | 86 |
missing data | 85 |
informed consent | 85 |
systematic review | 76 |
sample size | 72 |
controlled trials | 72 |
randomized controlled | 70 |
randomised controlled | 68 |
serious adverse | 63 |
data collection | 61 |
randomized clinical | 60 |
coronavirus disease | 59 |
public health | 58 |
respiratory syndrome | 57 |
cord uid | 56 |
doc id | 56 |
trial design | 54 |
phase iii | 53 |
health care | 53 |
versus standard | 51 |
phase i | 51 |
negative disconfirmation | 50 |
respiratory failure | 49 |
mechanical ventilation | 49 |
severe acute | 48 |
phase ii | 46 |
clinical practice | 46 |
safety data | 45 |
trial sequential | 43 |
united states | 43 |
healthcare workers | 42 |
first trial | 42 |
control group | 41 |
respiratory distress | 41 |
analysis showed | 40 |
additional file | 40 |
data will | 39 |
treatment effect | 39 |
novel coronavirus | 39 |
participants will | 39 |
distress syndrome | 38 |
statistical analysis | 38 |
trial results | 38 |
trial will | 38 |
cause mortality | 36 |
will also | 35 |
primary outcome | 34 |
pharmaceutical companies | 34 |
world health | 34 |
action sequence | 33 |
cancer patients | 33 |
syndrome coronavirus | 33 |
may also | 33 |
low certainty | 33 |
critically ill | 33 |
medical research | 33 |
statistical methods | 33 |
health organization | 32 |
twice daily | 32 |
intensive care | 32 |
developing countries | 31 |
showed evidence | 30 |
sequential analysis | 30 |
systematic reviews | 29 |
one trial | 29 |
chronic obstructive | 29 |
clinical study | 28 |
pulmonary disease | 28 |
trial participants | 28 |
age groups | 27 |
obstructive pulmonary | 27 |
observational studies | 27 |
outcome measures | 27 |
ill patients | 27 |
randomized trial | 27 |
cognitive flexibility | 27 |
patients will | 26 |
action sequences | 26 |
bubonic plague | 26 |
trial emulation | 26 |
trials may | 26 |
breast cancer | 26 |
drug administration | 25 |
critical care | 25 |
severe covid | 25 |
data protection | 25 |
institutional review | 24 |
confidence interval | 24 |
high risk | 24 |
ethics committee | 24 |
copd exacerbation | 23 |
adverse event | 23 |
living systematic | 23 |
free days | 23 |
secondary outcomes | 23 |
infectious diseases | 23 |
interim analysis | 23 |
relative risk | 23 |
within days | 22 |
health research | 22 |
exclusion criteria | 22 |
beneficial effect | 22 |
pneumonic plague | 22 |
patient safety | 22 |
steering committee | 22 |
vaccine candidates | 22 |
drug safety | 21 |
study protocol | 21 |
side effects | 21 |
versus placebo | 21 |
nonserious adverse | 21 |
led trials | 21 |
iii trials | 21 |
trial designs | 21 |
live home | 21 |
will need | 20 |
safety outcomes | 20 |
inclusion criteria | 20 |
study treatment | 20 |
regulatory agencies | 20 |
made available | 20 |
mg kg | 20 |
may need | 20 |
lung injury | 20 |
trial data | 20 |
remdesivir versus | 19 |
protocol deviations | 19 |
lopinavir ritonavir | 19 |
study design | 19 |
will likely | 19 |
cohort study | 19 |
data quality | 19 |
observational study | 19 |
undue influence | 19 |
care alone | 18 |
significant difference | 18 |
confirmed cases | 18 |
scientific community | 18 |
intervention period | 18 |
medical management | 18 |
randomized trials | 18 |
human subjects | 18 |
research team | 18 |
case report | 18 |
three age | 18 |
good clinical | 18 |
included trials | 18 |
safety monitoring | 18 |
acute lung | 18 |
nasal obstruction | 17 |
hand hygiene | 17 |
risk reduction | 17 |
ongoing clinical | 17 |
trial registration | 17 |
related ices | 17 |
full protocol | 17 |
copyright holder | 17 |
care versus | 17 |
will receive | 17 |
ii trials | 17 |
clinical studies | 17 |
least one | 16 |
tentative solution | 16 |
primary endpoint | 16 |
review boards | 16 |
data management | 16 |
medicines agency | 16 |
group will | 16 |
international license | 16 |
total number | 16 |
target trial | 16 |
data sharing | 16 |
individual patient | 16 |
older adults | 16 |
data analysis | 16 |
treatment effects | 16 |
hospitalized patients | 16 |
pregnant women | 16 |
granted medrxiv | 15 |
two trials | 15 |
information size | 15 |
type i | 15 |
chinese medicine | 15 |
task demands | 15 |
mask use | 15 |
registered trials | 15 |
social network | 15 |
authors declare | 15 |
com scientificreports | 15 |
data verification | 15 |
open access | 15 |
test trials | 15 |
research participation | 15 |
research participants | 15 |
convalescent plasma | 15 |
peer review | 15 |
author funder | 15 |
interventional trials | 15 |
miracle trial | 15 |
mean difference | 15 |
ongoing trials | 15 |
primary outcomes | 15 |
trials within | 15 |
jacobson hopper | 15 |
east respiratory | 14 |
traditional chinese | 14 |
data monitoring | 14 |
social distancing | 14 |
patient care | 14 |
required information | 14 |
preventive treatment | 14 |
treatment arms | 14 |
efficient solution | 14 |
analysis will | 14 |
systemic glucocorticoids | 14 |
control trials | 14 |
intermittent preventive | 14 |
trial conduct | 14 |
lung cancer | 14 |
cancer clinical | 14 |
pharmaceutical industry | 14 |
drug development | 14 |
path trial | 14 |
live oral | 14 |
adverse reactions | 14 |
sponsored trials | 14 |
risk factors | 14 |
nonhuman primates | 14 |
middle east | 14 |
competing interests | 14 |
interim analyses | 14 |
resource utilization | 14 |
dementia care | 14 |
sample sizes | 14 |
platform trials | 13 |
source control | 13 |
international clinical | 13 |
tentative solutions | 13 |
international conference | 13 |
trial registries | 13 |
analyses will | 13 |
trials using | 13 |
clinical improvement | 13 |
external validity | 13 |
living mapping | 13 |
master protocols | 13 |
eligibility criteria | 13 |
european medicines | 13 |
staff will | 13 |
task configuration | 13 |
trial completion | 13 |
septal surgery | 13 |
immune responses | 13 |
trials conducted | 13 |
trial integrity | 13 |
acute exacerbation | 13 |
take place | 13 |
patient data | 13 |
outcome measure | 13 |
impact score | 13 |
medical products | 12 |
study visits | 12 |
subgroup analyses | 12 |
drug trials | 12 |
clinical characteristics | 12 |
olds used | 12 |
phase iib | 12 |
consent form | 12 |
healthcare systems | 12 |
infectious disease | 12 |
compassionate use | 12 |
information technology | 12 |
investigators will | 12 |
alongside genv | 12 |
clinical data | 12 |
social media | 12 |
sick patients | 12 |
remains neutral | 12 |
adaptive trial | 12 |
malarial drugs | 12 |
respiratory syncytial | 12 |
nature remains | 12 |
institutional affiliations | 12 |
urgent need | 12 |
statistical monitoring | 12 |
safety assessment | 12 |
posted june | 12 |
patient will | 12 |
mental health | 12 |
rheumatoid arthritis | 12 |
large number | 12 |
published maps | 12 |
creative commons | 12 |
springer nature | 12 |
vaccine protection | 12 |
trial participation | 12 |
randomised trials | 12 |
two groups | 12 |
version posted | 12 |
generation victoria | 12 |
treatment group | 12 |
recovery trial | 12 |
jurisdictional claims | 12 |
single trial | 12 |
genv will | 12 |
will include | 12 |
olfactory information | 12 |
analysis plan | 12 |
publicly available | 12 |
i error | 12 |
trials will | 12 |
clinical care | 12 |
will take | 11 |
preliminary report | 11 |
supportive care | 11 |
colorectal cancer | 11 |
experimental group | 11 |
hypothetical strategy | 11 |
eligible patients | 11 |
malarial drug | 11 |
health emergency | 11 |
trial randomizing | 11 |
conducting clinical | 11 |
good enough | 11 |
study group | 11 |
monitoring committee | 11 |
vaccine trials | 11 |
may lead | 11 |
trials registered | 11 |
based medicine | 11 |
syncytial virus | 11 |
enough information | 11 |
clinical outcomes | 11 |
note springer | 11 |
randomized control | 11 |
evidence base | 11 |
treatment options | 11 |
problem solving | 11 |
patients treated | 11 |
network meta | 11 |
increased risk | 11 |
use scenarios | 11 |
grounded theory | 11 |
performance status | 11 |
potential treatments | 11 |
blog posts | 11 |
information systems | 11 |
vaccine safety | 11 |
early phase | 11 |
multiple trials | 11 |
two straws | 11 |
ethical principles | 11 |
sensitivity analysis | 11 |
care unit | 11 |
may include | 11 |
enrolled patients | 11 |
will provide | 11 |
adaptive designs | 11 |
vaccine development | 11 |
trial sponsors | 11 |
hydroxychloroquine versus | 11 |
study designs | 11 |
patients admitted | 11 |
regulatory authorities | 11 |
source data | 11 |
days will | 10 |
study will | 10 |
disease severity | 10 |
baseline characteristics | 10 |
cancer care | 10 |
ciprofloxacin mg | 10 |
trial sites | 10 |
treated states | 10 |
data may | 10 |
trials reported | 10 |
forest plot | 10 |
treatment arm | 10 |
randomised clinical | 10 |
review board | 10 |
younger children | 10 |
take part | 10 |
research questions | 10 |
risk ratio | 10 |
respiratory disease | 10 |
group sequential | 10 |
clinical decision | 10 |
research efforts | 10 |
vaccine trial | 10 |
respiratory viruses | 10 |
adults hospitalized | 10 |
children used | 10 |
nasal septum | 10 |
report form | 10 |
adverse effects | 10 |
analyses may | 10 |
outcomes will | 10 |
human research | 10 |
supplementary information | 10 |
scent trails | 10 |
trials registry | 10 |
high level | 10 |
completed trials | 10 |
control groups | 10 |
future research | 10 |
immune response | 10 |
clinical development | 10 |
site staff | 10 |
research council | 10 |
visual inspection | 10 |
among patients | 10 |
causal understanding | 10 |
nursing home | 10 |
developing world | 10 |
animal models | 10 |
new drug | 10 |
across trials | 10 |
sensitivity analyses | 10 |
research ethics | 10 |
quantify heterogeneity | 10 |
month follow | 10 |
statistical analyses | 10 |
primary subspecialty | 10 |
users may | 10 |
turbinate reduction | 9 |
study participants | 9 |
randomised trial | 9 |
electronic medical | 9 |
new drugs | 9 |
related missing | 9 |
policy trial | 9 |
research community | 9 |
kg twice | 9 |
principal investigator | 9 |
severe bronchiolitis | 9 |
coronavirus pandemic | 9 |
author impact | 9 |
risk assessment | 9 |
research activities | 9 |
exact test | 9 |
health authorities | 9 |
controlled clinical | 9 |
research enterprise | 9 |
determine whether | 9 |
efficient responses | 9 |
process evaluation | 9 |
medical records | 9 |
sunda pangolin | 9 |
virus disease | 9 |
registry platform | 9 |
care workers | 9 |
manis javanica | 9 |
effect size | 9 |
second trial | 9 |
therapeutic response | 9 |
results will | 9 |
publication bias | 9 |
tidal volumes | 9 |
ards network | 9 |
case study | 9 |
efficient method | 9 |
related missingness | 9 |
european countries | 9 |
implementation process | 9 |
interferon alpha | 9 |
commonly used | 9 |
picu stay | 9 |
central statistical | 9 |
available data | 9 |
monitoring board | 9 |
trial protocols | 9 |
national institutes | 9 |
current covid | 9 |
cancer research | 9 |
weighted mean | 9 |
phase trials | 9 |
statistically significant | 9 |
investigational products | 9 |
chloroquine diphosphate | 9 |
current pandemic | 9 |
across multiple | 9 |
ensemble modeling | 9 |
small sample | 9 |
medical masks | 9 |
pooled analysis | 9 |
health workers | 9 |
research findings | 9 |
hpa axis | 9 |
us food | 9 |
plaque psoriasis | 9 |
home orders | 9 |
sensory information | 9 |
genv data | 9 |
second stage | 9 |
blood pressure | 9 |
internal validity | 8 |
many ways | 8 |
written informed | 8 |
drug use | 8 |
residual odor | 8 |
replacement therapy | 8 |
index score | 8 |
dead ants | 8 |
alternative treatment | 8 |
personal use | 8 |
laboratory tests | 8 |
control trial | 8 |
empirical material | 8 |
influenza infection | 8 |
future trials | 8 |
severe psoriasis | 8 |
data entry | 8 |
belmont report | 8 |
care systems | 8 |
nasal patency | 8 |
one single | 8 |
iii trial | 8 |
primary endpoints | 8 |
study population | 8 |
day prednisone | 8 |
prone positioning | 8 |
identified trials | 8 |
combination therapy | 8 |
placebo group | 8 |
time points | 8 |
information accompanies | 8 |
huashan hospital | 8 |
rapid review | 8 |
personal protective | 8 |
controlled study | 8 |
will allow | 8 |
intervention group | 8 |
collected data | 8 |
north american | 8 |
ebola virus | 8 |
among others | 8 |
cancer cells | 8 |
consent process | 8 |
control arm | 8 |
viral infections | 8 |
ritonavir versus | 8 |
primary objective | 8 |
trial steering | 8 |
coronavirus pneumonia | 8 |
per group | 8 |
trial statistician | 8 |
nasal airway | 8 |
randomizing participants | 8 |
site monitoring | 8 |
target trials | 8 |
protection regulation | 8 |
natural history | 8 |
cohort studies | 8 |
olds made | 8 |
based quality | 8 |
icu patients | 8 |
care services | 8 |
data collected | 8 |
research process | 8 |
intravenous vitamin | 8 |
site initiation | 8 |
relevant data | 8 |
test trial | 8 |
southeast asia | 8 |
therapeutic interventions | 8 |
remote monitoring | 8 |
trials doi | 8 |
phase clinical | 8 |
primary analysis | 8 |
effects meta | 8 |
case series | 8 |
statistical power | 8 |
face mask | 8 |
intervention effects | 8 |
treatment policy | 8 |
two reviewers | 8 |
phase trial | 8 |
safety endpoints | 8 |
study drug | 8 |
treatment groups | 8 |
integrative cancer | 8 |
surfactant therapy | 8 |
multiple imputation | 8 |
orphan drug | 8 |
mycophenolate mofetil | 8 |
case reports | 8 |
two containers | 8 |
confidence intervals | 8 |
quality management | 8 |
eligible trials | 8 |
data meta | 8 |
ethics committees | 8 |
research project | 8 |
will require | 8 |
six trials | 8 |
olds versus | 8 |
parallel group | 8 |
adaptive clinical | 8 |
jwby formulas | 8 |
effective treatment | 8 |
test phase | 8 |
protective equipment | 8 |
related disruptions | 8 |
per protocol | 7 |
subgroup analysis | 7 |
trial recruitment | 7 |
kluwer health | 7 |
trial may | 7 |
treating covid | 7 |
per day | 7 |
long term | 7 |
surgical clinical | 7 |
related factors | 7 |
random errors | 7 |
trial protocol | 7 |
quality clinical | 7 |
new vaccines | 7 |
treatment will | 7 |
review process | 7 |
academic literature | 7 |
exogenous surfactant | 7 |
care system | 7 |
information will | 7 |
allocated treatment | 7 |
observed data | 7 |
study coordinators | 7 |
unauthorized reproduction | 7 |
bayesian adaptive | 7 |
renal replacement | 7 |
rare disease | 7 |
time zero | 7 |
zika virus | 7 |
go beyond | 7 |
prostate cancer | 7 |
decision makers | 7 |
will make | 7 |
data safety | 7 |
adjusted required | 7 |
research question | 7 |
additional analyses | 7 |
might also | 7 |
intervention will | 7 |
recent years | 7 |
severe disease | 7 |
participant safety | 7 |
error behaviour | 7 |
malaria prevention | 7 |
protocol amendments | 7 |
first days | 7 |
involving human | 7 |
tolerable errors | 7 |
caregiver burden | 7 |
trials randomizing | 7 |
cloth masks | 7 |
i trials | 7 |
monitoring boundaries | 7 |
reviewed trials | 7 |
rescue therapy | 7 |
main trial | 7 |
clinical trialists | 7 |
pandemic may | 7 |
protocol version | 7 |
kcdc guideline | 7 |
tolerable error | 7 |
efficient action | 7 |
different action | 7 |
high mortality | 7 |
trial research | 7 |
mortality rates | 7 |
supply chains | 7 |
healthcare system | 7 |
necrosis factor | 7 |
emerging infectious | 7 |
wolters kluwer | 7 |
type ii | 7 |
nursing homes | 7 |
research subjects | 7 |
descriptive statistics | 7 |
trial management | 7 |
data integrity | 7 |
cannabis use | 7 |
hospitalised patients | 7 |
participants may | 7 |
axillary temperature | 7 |
efficacy trials | 7 |
vaccine candidate | 7 |
confirmed probable | 7 |
patients randomised | 7 |
trials showed | 7 |
see table | 7 |
especially important | 7 |
research infrastructure | 7 |
disease control | 7 |
die within | 7 |
study drugs | 7 |
safety profile | 7 |
china clinical | 7 |
will continue | 7 |
trial sponsor | 7 |
uncorrected axillary | 7 |
cell lines | 7 |
days number | 7 |
working group | 7 |
safety information | 7 |
deviated septum | 7 |
tumor necrosis | 7 |
events will | 7 |
four straws | 7 |
randomizing patients | 7 |
west africa | 7 |
attending physician | 7 |
investigators must | 7 |
target infection | 7 |
principal investigators | 7 |
trial status | 7 |
versus medical | 7 |
adaptive design | 7 |
academic publication | 7 |
trials alongside | 7 |
time bias | 7 |
investigational drug | 7 |
basket trial | 7 |
study period | 7 |
research involving | 7 |
four groups | 7 |
associated pneumonia | 7 |
accelerated approval | 7 |
baseline severity | 7 |
three trials | 7 |
average trial | 7 |
european union | 7 |
malaria chemoprevention | 7 |
sequential monitoring | 7 |
positive results | 7 |
monoclonal antibody | 7 |
rapid research | 7 |
studies may | 7 |
core categories | 7 |
united kingdom | 7 |
without compromising | 7 |
trial date | 7 |
blood samples | 7 |
may occur | 7 |
quality assurance | 7 |
two different | 7 |
incentive payments | 7 |
choice task | 7 |
may help | 6 |
tablet users | 6 |
theoretical sampling | 6 |
mg per | 6 |
human use | 6 |
made efficient | 6 |
ii error | 6 |
investigate whether | 6 |
post hoc | 6 |
without results | 6 |
panel data | 6 |
every week | 6 |
time required | 6 |
red outward | 6 |
invasive mechanical | 6 |
medical sciences | 6 |
minimum dataset | 6 |
causal inference | 6 |
immortal time | 6 |
ethical approval | 6 |
iib trials | 6 |
randomized study | 6 |
conventional treatment | 6 |
completion date | 6 |
th april | 6 |
high quality | 6 |
longitudinal data | 6 |
led clinical | 6 |
oral cholera | 6 |
trial registry | 6 |
originally planned | 6 |
patient information | 6 |
th percentile | 6 |
foraging behaviour | 6 |
trials without | 6 |
direct benefit | 6 |
moderate covid | 6 |
medical care | 6 |
multicentre trial | 6 |
participants compared | 6 |
standard deviation | 6 |
different countries | 6 |
days within | 6 |
trial hydroxychloroquine | 6 |
trial enrollment | 6 |
wedge randomized | 6 |
treating physician | 6 |
trial investigators | 6 |
updated guidelines | 6 |
run length | 6 |
see also | 6 |
adult patients | 6 |
will explore | 6 |
testing chamber | 6 |
geriatric clinical | 6 |
efficacy data | 6 |
causally clear | 6 |
also apply | 6 |
iv twice | 6 |
clinical testing | 6 |
sequential analyses | 6 |
drug companies | 6 |
managing clinical | 6 |
red lines | 6 |
standard treatment | 6 |
patient willingness | 6 |
bubo size | 6 |
clinical effectiveness | 6 |
journal editors | 6 |
green dotted | 6 |
treatment discontinuation | 6 |
plague patients | 6 |
retrospective cohort | 6 |
clinically relevant | 6 |
dotted line | 6 |
tidal volume | 6 |
gender disparities | 6 |
decision making | 6 |
human trial | 6 |
experimental study | 6 |
conventional boundaries | 6 |
coordinator will | 6 |
emulation framework | 6 |
line shows | 6 |
lung disease | 6 |
metastatic colorectal | 6 |
decisions regarding | 6 |
arm trials | 6 |
target population | 6 |
reported outcome | 6 |
management group | 6 |
feasibility study | 6 |
takes place | 6 |
study staff | 6 |
related clinical | 6 |
severe plaque | 6 |
randomised evaluation | 6 |
case time | 6 |
trial findings | 6 |
month intervention | 6 |
potential impact | 6 |
standard supportive | 6 |
treatment trials | 6 |
reviewed publications | 6 |
trials related | 6 |
may influence | 6 |
many patients | 6 |
intravenous immunoglobulin | 6 |
trial identifier | 6 |
age group | 6 |
network analysis | 6 |
several studies | 6 |
research may | 6 |
care professionals | 6 |
medical record | 6 |
reporting parallel | 6 |
clinical protection | 6 |
scientific integrity | 6 |
currently available | 6 |
treat covid | 6 |
ratio reduction | 6 |
national institute | 6 |
calculated based | 6 |
food vs | 6 |
related trials | 6 |
search terms | 6 |
ml kg | 6 |
harmful effect | 6 |
will remain | 6 |
lung function | 6 |
methods used | 6 |
even though | 6 |
saudi arabia | 6 |
nairos trial | 6 |
many trials | 6 |
rapid learning | 6 |
pandemic related | 6 |
patients undergoing | 6 |
trials assessing | 6 |
one study | 6 |
study showed | 6 |
systematic errors | 6 |
expert consensus | 6 |
experimental vaccine | 6 |
arm studies | 6 |
home order | 6 |
many centers | 6 |
proactive prophylaxis | 6 |
useful information | 6 |
fda guidance | 6 |
summary statistics | 6 |
ipad pro | 6 |
new treatment | 6 |
outcome test | 6 |
standard protocol | 6 |
may require | 6 |
medrxiv preprint | 6 |
shows conventional | 6 |
rights reserved | 6 |
trial latency | 6 |
inferiority margin | 6 |
health records | 6 |
also need | 6 |
dexamethasone versus | 6 |
take oral | 6 |
plus interferon | 6 |
different types | 6 |
lupus erythematosus | 6 |
within genv | 6 |
platform trial | 6 |
bushen yiqi | 6 |
medical staff | 6 |
electronic health | 6 |
fatality rate | 6 |
trial coordination | 6 |
single target | 6 |
consort extension | 6 |
cancer xenografts | 6 |
pharmaceutical company | 6 |
recruitment bias | 6 |
randomisation will | 6 |
group randomised | 6 |
small number | 6 |
potential benefits | 6 |
general data | 6 |
information system | 6 |
colon cancer | 6 |
therapeutic agents | 6 |
gender gap | 6 |
nasal septal | 6 |
personal data | 6 |
hypothetical scenario | 6 |
blue line | 6 |
pan troglodytes | 6 |
qualitative research | 6 |
relatively small | 6 |
live intervention | 6 |
baited container | 6 |
volunteer support | 6 |
precision medicine | 6 |
improve patient | 6 |
dexamethasone group | 6 |
cluster randomised | 6 |
stage design | 6 |
futility line | 6 |
collect data | 6 |
academic medicine | 6 |
tcm syndrome | 6 |
monitoring plan | 6 |
licensure trials | 6 |
social networks | 6 |
high incidence | 6 |
outward sloping | 6 |
reporting items | 6 |
month period | 6 |
individual patients | 6 |
cluster randomized | 6 |
multicomponent intervention | 6 |
factors associated | 6 |
health system | 6 |
rcts may | 6 |
may result | 6 |
primary completion | 6 |
sloping red | 6 |
see supplementary | 6 |
gastrointestinal bleeding | 6 |
surgical mask | 6 |
antipsychotic medication | 6 |
preferred reporting | 6 |
subjectively unreasonable | 6 |
time series | 6 |
monitoring visits | 6 |
best practice | 6 |
ethically acceptable | 6 |
patients experiencing | 6 |
median survival | 6 |
across different | 6 |
remote access | 6 |
clinical efficacy | 6 |
sites will | 5 |
consent forms | 5 |
surgical trials | 5 |
maintenance treatment | 5 |
negative correlation | 5 |
study procedures | 5 |
many countries | 5 |
community members | 5 |
samples will | 5 |
unreasonable decisions | 5 |
income countries | 5 |
participating sites | 5 |
study results | 5 |
inward sloping | 5 |
allowed us | 5 |
trials across | 5 |
oral administration | 5 |
monitoring boards | 5 |
informal caregivers | 5 |
interviews will | 5 |
systolic blood | 5 |
adaptive structuration | 5 |
national health | 5 |
new clinical | 5 |
short period | 5 |
will end | 5 |
trial comparing | 5 |
multiple interventions | 5 |
research institutions | 5 |
considered serious | 5 |
quality assessment | 5 |
recruitment intervention | 5 |
different interventions | 5 |
research institute | 5 |
trial using | 5 |
trials research | 5 |
genv may | 5 |
vaccine efficacy | 5 |
trials used | 5 |
event endpoints | 5 |
nose score | 5 |
first time | 5 |
trial reporting | 5 |
will follow | 5 |
preliminary results | 5 |
adjusted life | 5 |
assessment time | 5 |
solidarity trial | 5 |
management arm | 5 |
careful consideration | 5 |
mg orally | 5 |
pandemic influenza | 5 |
plus ciprofloxacin | 5 |
gold standard | 5 |
policy strategy | 5 |
face contact | 5 |
theory method | 5 |
orally twice | 5 |
study objectives | 5 |
national guidelines | 5 |
will use | 5 |
scheduled visits | 5 |
additional sensitivity | 5 |
also used | 5 |
quadrivalent rhesus | 5 |
clinically significant | 5 |
search strategy | 5 |
ethical considerations | 5 |
inflammatory cytokines | 5 |
growth rate | 5 |
trial monitoring | 5 |
tests will | 5 |
service innovation | 5 |
wedge futility | 5 |
supplementary table | 5 |
countries regions | 5 |
resource allocation | 5 |
writing group | 5 |
pain scale | 5 |
first last | 5 |
international guidelines | 5 |
trial team | 5 |
health policy | 5 |
systemic lupus | 5 |
treatment interruptions | 5 |
healthy volunteers | 5 |
hygiene alone | 5 |
septal deviation | 5 |
global pandemic | 5 |
funding bodies | 5 |
study sponsors | 5 |
beneficial effects | 5 |
care group | 5 |
main limitation | 5 |
rhesus rotavirus | 5 |
research projects | 5 |
reference number | 5 |
individual consistency | 5 |
orchid trial | 5 |
inefficient action | 5 |
initial negative | 5 |
individual trials | 5 |
endangered species | 5 |
per trial | 5 |
heart failure | 5 |
mitigation measures | 5 |
trials comparing | 5 |
dosage chloroquine | 5 |
coronavirus infection | 5 |
final manuscript | 5 |
defined based | 5 |
trial reported | 5 |
treatment trial | 5 |
sectional study | 5 |
patient distrust | 5 |
viral infection | 5 |
important role | 5 |
care units | 5 |
observational data | 5 |
potential covid | 5 |
approved drugs | 5 |
ethics approval | 5 |
health services | 5 |
healthcare providers | 5 |
terminology criteria | 5 |
error may | 5 |
first step | 5 |
healthcare products | 5 |
trial drugs | 5 |
study unblinding | 5 |
assessed days | 5 |
routinely collected | 5 |
acoustic information | 5 |
common terminology | 5 |
trial subjects | 5 |
national cancer | 5 |
trials website | 5 |
respiratory tract | 5 |
streptomycin plus | 5 |
median number | 5 |
editorial board | 5 |
viral clearance | 5 |
commons licence | 5 |
remove straws | 5 |
protocol analysis | 5 |
older children | 5 |
improve health | 5 |
corresponding author | 5 |
respiratory protection | 5 |
th stage | 5 |
covid pandemic | 5 |
pregnancy trials | 5 |
safety analyses | 5 |
multicentre trials | 5 |
results suggest | 5 |
trial compared | 5 |
infected patients | 5 |
case growth | 5 |
cohort multiple | 5 |
one patient | 5 |
products regulatory | 5 |
see section | 5 |
low dose | 5 |
protocol items | 5 |
maximum dose | 5 |
patient outcomes | 5 |
literature review | 5 |
clear task | 5 |
mechanically ventilated | 5 |
main outcomes | 5 |
per year | 5 |
trials compared | 5 |
old children | 5 |
pilot study | 5 |
mapping tool | 5 |
awake prone | 5 |
may provide | 5 |
medical community | 5 |
therapeutic efficacy | 5 |
statistical principles | 5 |
treatment regimens | 5 |
advisory unit | 5 |
first presented | 5 |
first two | 5 |
statistical models | 5 |
sloping lines | 5 |
pandemic situation | 5 |
issues related | 5 |
chloroquine phosphate | 5 |
health systems | 5 |
discovery rate | 5 |
imaging follow | 5 |
trial suspension | 5 |
information alone | 5 |
remaining trials | 5 |
study using | 5 |
pandemic effects | 5 |
nasal spray | 5 |
study reports | 5 |
results published | 5 |
care coordination | 5 |
policy evaluations | 5 |
overall trial | 5 |
last years | 5 |
side effect | 5 |
initiated trials | 5 |
five straws | 5 |
rate ratio | 5 |
patient follow | 5 |
trials based | 5 |
case counts | 5 |
project manager | 5 |
risks analyses | 5 |
influenza transmission | 5 |
consent will | 5 |
i trial | 5 |
logistic regression | 5 |
surgical intervention | 5 |
copd exacerbations | 5 |
viral load | 5 |
case numbers | 5 |
health policies | 5 |
different clinical | 5 |
committee will | 5 |
clinically important | 5 |
quintet recruitment | 5 |
general principles | 5 |
label use | 5 |
protocol deviation | 5 |
first stage | 5 |
will report | 5 |
adequately powered | 5 |
study team | 5 |
competing risks | 5 |
calendar time | 5 |
following negative | 5 |
changing task | 5 |
analysis population | 5 |
regulatory agency | 5 |
comparison states | 5 |
stakeholder engagement | 5 |
multiple comparisons | 5 |
findings show | 5 |
tcm herbs | 5 |
relevant research | 5 |
time periods | 5 |
second review | 5 |
within cohorts | 5 |
may continue | 5 |
reporting data | 5 |
chief investigator | 5 |
two separate | 5 |
ethical concerns | 5 |
cancer chemotherapy | 5 |
interactive mapping | 5 |
analysis methods | 5 |
fish oil | 5 |
new treatments | 5 |
related reasons | 5 |
cholera vaccine | 5 |
hospital admission | 5 |
cell lung | 5 |
existing literature | 5 |
might need | 5 |
objectively unreasonable | 5 |
rapidly changing | 5 |
worn continually | 5 |
flexibility across | 5 |
neck cancer | 5 |
performed using | 5 |
working groups | 5 |
quality control | 5 |
pangolins native | 5 |
orphan drugs | 5 |
comparative effectiveness | 5 |
quality evidence | 5 |
significantly reduced | 5 |
promising results | 5 |
infection risk | 5 |
treatment response | 5 |
mashhad university | 5 |
propensity score | 5 |
research designs | 5 |
acute exacerbations | 5 |
transplant patients | 5 |
regulatory bodies | 5 |
patients infected | 5 |
may well | 5 |
patients hospitalized | 5 |
false discovery | 5 |
composite strategy | 5 |
knowledge gap | 5 |
states food | 5 |
mortality rate | 5 |
research network | 5 |
well people | 5 |
many years | 5 |
identified one | 5 |
disease outbreaks | 5 |
data using | 5 |
activated protein | 5 |
disease incidence | 5 |
medical journals | 5 |
novel therapeutic | 5 |
positive patients | 5 |
recruitment rate | 5 |
polio vaccine | 5 |
individual level | 5 |
citation score | 5 |
cov infection | 5 |
paying research | 5 |
sunda pangolins | 5 |
clinically appropriate | 5 |
trial efficacy | 5 |
completion latency | 5 |
used different | 5 |
medical mask | 5 |
pandemic will | 5 |
statistical issues | 5 |
blood tests | 5 |
reassortant vaccine | 5 |
systemic glucocorticoid | 5 |
study nurse | 5 |
adjunctive therapy | 5 |
registration date | 5 |
days alive | 5 |
medical journal | 5 |
nasal blockage | 5 |
testing apparatus | 5 |
chronic rhinosinusitis | 5 |
allocation concealment | 5 |
structuration theory | 5 |
eight trials | 5 |
trials evaluating | 5 |
related deaths | 5 |
nasal septoplasty | 4 |
key elements | 4 |
new trials | 4 |
primary investigator | 4 |
efficient response | 4 |
genv principles | 4 |
trials need | 4 |
information sheet | 4 |
will evaluate | 4 |
ribavirin plus | 4 |
day mortality | 4 |
effects models | 4 |
straw directly | 4 |
trial process | 4 |
prior research | 4 |
target disease | 4 |
specific information | 4 |
care planning | 4 |
physical interventions | 4 |
may increase | 4 |
review will | 4 |
better start | 4 |
hospital discharge | 4 |
action plan | 4 |
voluntary use | 4 |
selection bias | 4 |
may impact | 4 |
person visits | 4 |
high flow | 4 |
well tolerated | 4 |
intravenous curcumin | 4 |
deemed clinically | 4 |
enrolled participants | 4 |
paramount importance | 4 |
received approval | 4 |
likely need | 4 |
product monograph | 4 |
response rate | 4 |
user behaviour | 4 |
give consent | 4 |
better understanding | 4 |
familiar formatting | 4 |
international standards | 4 |
stress scale | 4 |
multinational registry | 4 |
intercurrent events | 4 |
respiratory rate | 4 |
flow diagram | 4 |
demands changed | 4 |
large proportion | 4 |
realistic intervention | 4 |
significance level | 4 |
hubei province | 4 |
research data | 4 |
face masks | 4 |
recruitment period | 4 |
multiple testing | 4 |
trial quality | 4 |
care reduces | 4 |
statistical code | 4 |
generation vaccines | 4 |
therapies may | 4 |
randomly assigned | 4 |
less relevant | 4 |
ring vaccination | 4 |
primary estimand | 4 |
research system | 4 |
standard procedures | 4 |
us fda | 4 |
contralateral turbinate | 4 |
science research | 4 |
treatments due | 4 |
live components | 4 |
received honoraria | 4 |
children made | 4 |
general medical | 4 |
based treatment | 4 |
home visits | 4 |
interrupted time | 4 |
plasma versus | 4 |
index scores | 4 |
supplementary material | 4 |
virtual visits | 4 |
acute generalized | 4 |
trial began | 4 |
recent publications | 4 |
last authorship | 4 |
solid lids | 4 |
difference across | 4 |
betweenness centrality | 4 |
regulatory requirements | 4 |
vaccine pe | 4 |
nan doi | 4 |
removing straws | 4 |
shown apparent | 4 |
resource use | 4 |
full years | 4 |
huang qin | 4 |
technical requirements | 4 |
study protocols | 4 |
must provide | 4 |
olfactory condition | 4 |
early childhood | 4 |
currently ongoing | 4 |
study completion | 4 |
raw data | 4 |
neuropsychiatric symptoms | 4 |
frequency oscillatory | 4 |
patients per | 4 |
trials reporting | 4 |
research protocol | 4 |
inflammatory cytokine | 4 |
respiratory symptoms | 4 |
generalized exanthematous | 4 |
national level | 4 |
modified natural | 4 |
dose mg | 4 |
seamless clinical | 4 |
per dose | 4 |
stepped wedge | 4 |
author role | 4 |
benefit ratio | 4 |
deemed unusable | 4 |
log cases | 4 |
tipping point | 4 |
max mg | 4 |
work closely | 4 |
estimand framework | 4 |
commons attribution | 4 |
utmost importance | 4 |
mental state | 4 |
investigational product | 4 |
rotavirus vaccine | 4 |
data items | 4 |
experimental treatment | 4 |
label non | 4 |
protocol violations | 4 |
academic institutions | 4 |
important outcomes | 4 |
multiple outcomes | 4 |
time constraints | 4 |
live ants | 4 |
administrative datasets | 4 |
basket clinical | 4 |
trials currently | 4 |
plague cases | 4 |
routine clinical | 4 |
named severe | 4 |
ipm will | 4 |
outcomes data | 4 |
nasal outcome | 4 |
clinical course | 4 |
hospital visits | 4 |
group trial | 4 |
hospital setting | 4 |
disease patients | 4 |
error process | 4 |
allocation ratio | 4 |
stop dates | 4 |
public registries | 4 |
condition consisted | 4 |
continuously inform | 4 |
patients receiving | 4 |
bias trials | 4 |
considered significant | 4 |
interferon beta | 4 |
extracted data | 4 |
trial approval | 4 |
label drug | 4 |
five safes | 4 |
volunteer coordinators | 4 |
jia wei | 4 |
study conduct | 4 |
project management | 4 |
mass media | 4 |
acute ischemic | 4 |
influenzae type | 4 |
complete trials | 4 |
controlled vocabularies | 4 |
new therapies | 4 |
probable bubonic | 4 |
across species | 4 |
users appropriate | 4 |
evaluate vaccine | 4 |
may cause | 4 |
results may | 4 |
avoid costly | 4 |
scientific discoveries | 4 |
coronavirus named | 4 |
clinical pharmacology | 4 |
public involvement | 4 |
remote consent | 4 |
mainly driven | 4 |
unmet clinical | 4 |
american trials | 4 |
random effects | 4 |
cochrane handbook | 4 |
related activities | 4 |
spontaneous understanding | 4 |
results show | 4 |
supplementary video | 4 |
north america | 4 |
conducted according | 4 |
significant increase | 4 |
disruptions due | 4 |
larger sample | 4 |
waiving consent | 4 |
oscillatory ventilation | 4 |
provide consent | 4 |
use disorder | 4 |
make use | 4 |
ensure safety | 4 |
rsv severe | 4 |
medical history | 4 |
physician investigators | 4 |
care trials | 4 |
accessed july | 4 |
potential participants | 4 |
living project | 4 |
developing covid | 4 |
manis tricuspis | 4 |
trial activities | 4 |
future work | 4 |
nv rhinospirometer | 4 |
mg twice | 4 |
published trials | 4 |
monitoring room | 4 |
large scale | 4 |
ethical issue | 4 |
relatively low | 4 |
data errors | 4 |
patient reported | 4 |
emergency regulation | 4 |
open label | 4 |
pulmonary surfactant | 4 |
patient management | 4 |
prognostic factors | 4 |
chinese clinical | 4 |
social value | 4 |
dementia plan | 4 |
assessment will | 4 |
rotavirus vaccines | 4 |
size calculation | 4 |
nct number | 4 |
letter serves | 4 |
older persons | 4 |
care time | 4 |
similar viruses | 4 |
cardiovascular trials | 4 |
retrospective study | 4 |
within phase | 4 |
cancer therapies | 4 |
ciprofloxacin alone | 4 |
placebo plus | 4 |
current situation | 4 |
user experience | 4 |
clinical investigation | 4 |
effects model | 4 |
informative censoring | 4 |
efficiency across | 4 |
trial effect | 4 |
review processes | 4 |
identify new | 4 |
pandemic onset | 4 |
medical therapy | 4 |
coordinating centres | 4 |
equal number | 4 |
support trials | 4 |
ritonavir plus | 4 |
will continuously | 4 |
infections may | 4 |
monitoring activities | 4 |
alternative mechanisms | 4 |
across countries | 4 |
analysis set | 4 |
rapidly spreading | 4 |
study populations | 4 |
average latency | 4 |
children born | 4 |
licensure surveillance | 4 |
task completion | 4 |
efficient strategy | 4 |
pandemic periods | 4 |
early stages | 4 |
sequences used | 4 |
trial number | 4 |
study without | 4 |
process will | 4 |
occur due | 4 |
way forward | 4 |
membrane oxygenation | 4 |
trial application | 4 |
growth factor | 4 |
improved survival | 4 |
vaccine side | 4 |
previously published | 4 |
perform meta | 4 |
stable chronic | 4 |
plague season | 4 |
timely manner | 4 |
design features | 4 |
available evidence | 4 |
receive placebo | 4 |
also identified | 4 |
study suggests | 4 |
multiple diseases | 4 |
molecular targets | 4 |
parties involved | 4 |
trial interventions | 4 |
collaborative research | 4 |
large platform | 4 |
put forward | 4 |
ards ali | 4 |
two stages | 4 |
different categories | 4 |
distrust group | 4 |
trials per | 4 |
health practice | 4 |
learning health | 4 |
virus infection | 4 |
genv proposes | 4 |
cumulative network | 4 |
trials working | 4 |
surrogate outcomes | 4 |
primary efficacy | 4 |
patient population | 4 |
comparing two | 4 |
collected health | 4 |
tumor types | 4 |
cognitive impairment | 4 |
industrialized countries | 4 |
find food | 4 |
registered clinical | 4 |
important research | 4 |
allocation will | 4 |
kg iv | 4 |
care research | 4 |
respiratory diseases | 4 |
septoplasty versus | 4 |
med doi | 4 |
recruitment process | 4 |
first case | 4 |
traditional clinical | 4 |
clinical cancer | 4 |
research coordinators | 4 |
recent study | 4 |
data without | 4 |
vaccine adverse | 4 |
patient recruitment | 4 |
specific patient | 4 |
make research | 4 |
chronic idiopathic | 4 |
overcome negative | 4 |
related events | 4 |
macbook pro | 4 |
inferior turbinate | 4 |
less likely | 4 |
potential benefit | 4 |
ischemic stroke | 4 |
safety issues | 4 |
data linkage | 4 |
preserving clinical | 4 |
pharmaceutical interventions | 4 |
may vary | 4 |
cochrane collaboration | 4 |
protection act | 4 |
timely fashion | 4 |
respiratory medicine | 4 |
sponsored clinical | 4 |
investigational site | 4 |
authors read | 4 |
financial support | 4 |
reject realistic | 4 |
mometasone furoate | 4 |
study report | 4 |
cases per | 4 |
qualitative analysis | 4 |
trial intermittent | 4 |
telephone calls | 4 |
interventional clinical | 4 |
one treatment | 4 |
comparative study | 4 |
two authors | 4 |
clarify whether | 4 |
sequence will | 4 |
significant negative | 4 |
tyrosine kinase | 4 |
septic shock | 4 |
data issues | 4 |
total sample | 4 |
may switch | 4 |
cancer treatment | 4 |
care arm | 4 |
european directive | 4 |
data handling | 4 |
time period | 4 |
comparisons across | 4 |
important difference | 4 |
forms will | 4 |
analysis plans | 4 |
nasal high | 4 |
treatment period | 4 |
patients enrolled | 4 |
first trials | 4 |
research studies | 4 |
appropriation literature | 4 |
trial assessments | 4 |
multiple therapies | 4 |
statistical computing | 4 |
without azithromycin | 4 |
first interim | 4 |
biomedical research | 4 |
eudract database | 4 |
event rate | 4 |
consideration may | 4 |
oral corticosteroids | 4 |
patients recruited | 4 |
data cleaning | 4 |
trials date | 4 |
submitting author | 4 |
outcome data | 4 |
trial activation | 4 |
chi shao | 4 |
relative stress | 4 |
cultural values | 4 |
risk patients | 4 |
future pandemics | 4 |
research staff | 4 |
trials group | 4 |
preclinical studies | 4 |
collecting data | 4 |
causal effects | 4 |
economic impact | 4 |
database lock | 4 |
us federal | 4 |
accumulating data | 4 |
new protocol | 4 |
deficient mice | 4 |
care management | 4 |
trial start | 4 |
largest trial | 4 |
laboratory data | 4 |
intervention components | 4 |
us national | 4 |
young children | 4 |
subspecialty designation | 4 |
concomitant medication | 4 |
ethical standards | 4 |
immunological correlate | 4 |
health professionals | 4 |
community health | 4 |
international committee | 4 |
trial dataset | 4 |
cancer institute | 4 |
global health | 4 |
previous research | 4 |
new sites | 4 |
apparent efficacy | 4 |
clinically meaningful | 4 |
effect estimates | 4 |
trials testing | 4 |
will occur | 4 |
primary care | 4 |
senior authorship | 4 |
remdesivir might | 4 |
high contagiousness | 4 |
time point | 4 |
next exacerbation | 4 |
site selection | 4 |
formulas plus | 4 |
expediting dissemination | 4 |
outcome assessors | 4 |
iii rcts | 4 |
similar manner | 4 |
confirmed covid | 4 |
treat analysis | 4 |
evaluate whether | 4 |
superiority hypotheses | 4 |
final cumulative | 4 |
international classification | 4 |
multiple sites | 4 |
educational programs | 4 |
clinical relevance | 4 |
ongoing trial | 4 |
tcm treatment | 4 |
complex interventions | 4 |
open coding | 4 |
specific treatment | 4 |
new approaches | 4 |
based care | 4 |
allocation sequence | 4 |
iii studies | 4 |
small cell | 4 |
experimental treatments | 4 |
authors contributed | 4 |
tested previously | 4 |
examine whether | 4 |
research organization | 4 |
advisory board | 4 |
treatment interventions | 4 |
treatment regimen | 4 |
widely used | 4 |
research oversight | 4 |
fourfold increase | 4 |
children spontaneously | 4 |
species differences | 4 |
across age | 4 |
data sets | 4 |
single trials | 4 |
research funding | 4 |
study nurses | 4 |
surgical arm | 4 |
flow therapy | 4 |
relevant information | 4 |
pangolins may | 4 |
world evidence | 4 |
treatment allocation | 4 |
antibody titre | 4 |
performed remotely | 4 |
study endpoints | 4 |
randomized placebo | 4 |
safety outcome | 4 |
core minimal | 4 |
atopic dermatitis | 4 |
individual trial | 4 |
health data | 4 |
enrolling patients | 4 |
clinical significance | 4 |
kg every | 4 |
trial authors | 4 |
clinical outcome | 4 |
severe atopic | 4 |
health centres | 4 |
qualitative interviews | 4 |
will probably | 4 |
new approach | 4 |
home patients | 4 |
additional days | 4 |
significant effect | 4 |
sometimes known | 4 |
medication review | 4 |
based research | 4 |
incidence value | 4 |
day follow | 4 |
intravenous ciprofloxacin | 4 |
wei bushen | 4 |
exanthematous pustulosis | 4 |
sars coronavirus | 4 |
statistical approach | 4 |
research must | 4 |
sharing platform | 4 |
transplant recipients | 4 |
drug discovery | 4 |
best possible | 4 |
general public | 4 |
conduct trials | 4 |
ciprofloxacin monotherapy | 4 |
receive jwby | 4 |
improve clinical | 4 |
independent living | 4 |
different things | 4 |
rapidly evaluate | 4 |
blind study | 4 |
using cohorts | 4 |
less toxic | 4 |
across phases | 4 |
allergic reactions | 4 |
deviated nasal | 4 |
available information | 4 |
safety reporting | 4 |
simulation study | 4 |
historical data | 4 |
edged sword | 4 |
assess whether | 4 |
effect meta | 4 |
renal function | 4 |
additional information | 4 |
trial staff | 4 |
lessons learned | 4 |
limited resources | 4 |
haemophilus influenzae | 4 |
extracorporeal membrane | 4 |
case fatality | 4 |
will meet | 4 |
every trial | 4 |
average across | 3 |
will work | 3 |
nasal inspiratory | 3 |
truth survival | 3 |
may allow | 3 |
worn intermittently | 3 |
ensure patient | 3 |
depressive symptoms | 3 |
cancer treatments | 3 |
nhs care | 3 |
conditional error | 3 |
trials enrolled | 3 |
naturally occurring | 3 |
higher rates | 3 |
adaptive covid | 3 |
trial id | 3 |
user may | 3 |
biological therapies | 3 |
data unblinding | 3 |
intervention groups | 3 |
enroll patients | 3 |
cancer therapy | 3 |
word level | 3 |
source register | 3 |
whole blood | 3 |
vaccine developed | 3 |
conservative estimate | 3 |
false positive | 3 |
treatment conditions | 3 |
may offer | 3 |
marketing drug | 3 |
disease epidemics | 3 |
crf table | 3 |
current public | 3 |
previous studies | 3 |
used investigational | 3 |
vertical plane | 3 |
figshare project | 3 |
third reviewer | 3 |
particularly relevant | 3 |
coding scheme | 3 |
phone call | 3 |
oral ciprofloxacin | 3 |
solve problems | 3 |
will often | 3 |
conventional medical | 3 |
dwelling persons | 3 |
endpoints may | 3 |
financial incentives | 3 |
will lead | 3 |
live vaccines | 3 |
legal advocate | 3 |
recombinant interferon | 3 |
hydroxychloroquine chloroquine | 3 |
general health | 3 |
bias due | 3 |
tree pangolin | 3 |
unexpected serious | 3 |
probable case | 3 |
suspected unexpected | 3 |
intervention start | 3 |
best interest | 3 |
user acceptance | 3 |
experimental interventions | 3 |
larger numbers | 3 |
variables will | 3 |
trial outcomes | 3 |
trials require | 3 |
poor knowledge | 3 |
primary hypothesis | 3 |
reported deaths | 3 |
ethically permissible | 3 |
weaver ants | 3 |
based interventions | 3 |
trials include | 3 |
ciprofloxacin group | 3 |
involving patients | 3 |
controlled phase | 3 |
restricted access | 3 |
often used | 3 |
baloxavir marboxil | 3 |
gilead sciences | 3 |
target infections | 3 |
spirit statement | 3 |
rotavirus reassortant | 3 |
integrative treatment | 3 |
true emergencies | 3 |
paediatric cancer | 3 |
medications used | 3 |
pvc tube | 3 |
will introduce | 3 |
iii randomized | 3 |
kinase inhibitor | 3 |
based cohort | 3 |
planned sample | 3 |
design elements | 3 |
mometasone nasal | 3 |
review evaluating | 3 |
disease caused | 3 |
level data | 3 |
data patterns | 3 |
post randomisation | 3 |
device trials | 3 |
based mitigation | 3 |
minimal clinically | 3 |
reporting systematic | 3 |
pandemic date | 3 |
note taking | 3 |
induced thrombocytopenia | 3 |
preliminary formulations | 3 |
also inhibits | 3 |
loved one | 3 |
poor performance | 3 |
healthcare settings | 3 |
three phases | 3 |
first configuration | 3 |
earlier studies | 3 |
phone calls | 3 |
virus vaccine | 3 |
practice may | 3 |
sputum samples | 3 |
support systems | 3 |
vaccine strain | 3 |
exclusively enrolled | 3 |
contingency measures | 3 |
press release | 3 |
integrative physicians | 3 |
provide guidance | 3 |
industrysponsored trials | 3 |
master protocol | 3 |
short time | 3 |
among health | 3 |
contingency plans | 3 |
signed consent | 3 |
five patients | 3 |
patients already | 3 |
nhs foundation | 3 |
assessment based | 3 |
overcome disconfirmation | 3 |
appropriate analysis | 3 |
increased use | 3 |
trials safety | 3 |
primary publication | 3 |
ovarian cancer | 3 |
specific questions | 3 |
reflection time | 3 |
two phase | 3 |
successful treatment | 3 |
investigator will | 3 |
writing committee | 3 |
swine flu | 3 |
metal mesh | 3 |
subject study | 3 |
versus days | 3 |
single mg | 3 |
factors related | 3 |
diagnostic test | 3 |
management strategy | 3 |
informant questionnaire | 3 |
neurovascular research | 3 |
clinical results | 3 |
randomized using | 3 |
trial activity | 3 |
prevalent cases | 3 |
adverse reaction | 3 |
incomplete data | 3 |
harmful effects | 3 |
control design | 3 |
i study | 3 |
test apparatus | 3 |
immunogenicity assays | 3 |
drug trial | 3 |
committee approval | 3 |
making sense | 3 |
constraints needed | 3 |
will country | 3 |
even greater | 3 |
trial ends | 3 |
reactive protein | 3 |
users use | 3 |
knowledge translation | 3 |
multiorgan failure | 3 |
readily available | 3 |
free survival | 3 |
include patient | 3 |
appropriate consent | 3 |
psoriatic arthritis | 3 |
medical treatment | 3 |
recent review | 3 |
become increasingly | 3 |
higher risk | 3 |
conjugate vaccine | 3 |
clinical needs | 3 |
intravenous quercetin | 3 |
placebo provided | 3 |
artery disease | 3 |
streptomycin ciprofloxacin | 3 |
ethnic minorities | 3 |
two chinese | 3 |
studies published | 3 |
relevant clinical | 3 |
observational cohort | 3 |
authorship score | 3 |
th immune | 3 |
interstitial lung | 3 |
new york | 3 |
emptive treatment | 3 |
high impact | 3 |
head neck | 3 |
registry analysis | 3 |
basic understanding | 3 |
information technologies | 3 |
may th | 3 |
peak nasal | 3 |
offering payment | 3 |
identifying benefits | 3 |
asian pangolins | 3 |
vaccine immunogenicity | 3 |
sectional analysis | 3 |
normally distributed | 3 |
alopecia areata | 3 |
unprotected healthcare | 3 |
research associate | 3 |
healthy individuals | 3 |
treatment assignment | 3 |
point estimates | 3 |
scientific reports | 3 |
informal care | 3 |
clinical evaluation | 3 |
efficacy outcomes | 3 |
rcts evaluating | 3 |
short form | 3 |
surgical treatment | 3 |
nasal packing | 3 |
implementation research | 3 |
next step | 3 |
changes made | 3 |
funding agencies | 3 |
solution may | 3 |
random effect | 3 |
severe side | 3 |
two reasons | 3 |
patient experience | 3 |
trials use | 3 |
inconclusive results | 3 |
decisions will | 3 |
preventive interventions | 3 |
secondary care | 3 |
assistive technology | 3 |
potential treatment | 3 |
key aspects | 3 |
given time | 3 |
different strategies | 3 |
maximum probability | 3 |
distributive justice | 3 |
author names | 3 |
product development | 3 |
will discuss | 3 |
weighted average | 3 |
significant results | 3 |
clinical investigators | 3 |
term effects | 3 |
tonifying kidney | 3 |
separate data | 3 |
modeling groups | 3 |
maximum follow | 3 |
avoid unnecessary | 3 |
using multiple | 3 |
table presents | 3 |
three days | 3 |
mucocutaneous candidiasis | 3 |
fully informed | 3 |
acceptance model | 3 |
based evidence | 3 |
standardized data | 3 |
must also | 3 |
investigators might | 3 |
site investigators | 3 |
colchicine added | 3 |
simple trials | 3 |
virtual research | 3 |
social sciences | 3 |
innovative clinical | 3 |
study set | 3 |
health science | 3 |
similar participants | 3 |
system use | 3 |
diagnostic tests | 3 |
telehealth may | 3 |
recruitment status | 3 |
general hospital | 3 |
intentional challenge | 3 |
opening remarks | 3 |
global clinical | 3 |
interventions supporting | 3 |
physical contact | 3 |
two home | 3 |
continue investigative | 3 |
may eventually | 3 |
network visualization | 3 |
daily dose | 3 |
received funding | 3 |
cancer drug | 3 |
consent based | 3 |
report will | 3 |
outpatient setting | 3 |
high transmission | 3 |
rapid diagnostic | 3 |
patients may | 3 |
grade unblinding | 3 |
innovative therapies | 3 |
incentives will | 3 |
carefully considered | 3 |
new vaccine | 3 |
related research | 3 |
physician may | 3 |
randomized patients | 3 |
psychiatric symptoms | 3 |
distrust pharmaceutical | 3 |
multiple countries | 3 |
public places | 3 |
patients without | 3 |
active vaccine | 3 |
trial sample | 3 |
future patients | 3 |
one hand | 3 |
therapeutic options | 3 |
external unplanned | 3 |
organizational members | 3 |
universal face | 3 |
stress reduction | 3 |
remain unchanged | 3 |
become available | 3 |
plus lopinavir | 3 |
potentially useful | 3 |
sick people | 3 |
inform best | 3 |
author details | 3 |
adaptive platform | 3 |
human challenge | 3 |
death due | 3 |
arm will | 3 |
pivotal trials | 3 |
personal experience | 3 |
atopic eczema | 3 |
groups will | 3 |
myasthenia gravis | 3 |
will recruit | 3 |
danish national | 3 |
will reduce | 3 |
executive function | 3 |
supportive therapy | 3 |
potential confounders | 3 |
data methods | 3 |
existing treatments | 3 |
within hours | 3 |
inferential statistical | 3 |
paediatric intensive | 3 |
london school | 3 |
eight test | 3 |
care staff | 3 |
gorillas tested | 3 |
trials initiated | 3 |
unproven therapies | 3 |
data processing | 3 |
oral rotavirus | 3 |
candidate vaccines | 3 |
medical practice | 3 |
participating centers | 3 |
previous sections | 3 |
children completed | 3 |
will assess | 3 |
participants per | 3 |
blinded data | 3 |
personnel will | 3 |
data sources | 3 |
learning systems | 3 |
core outcome | 3 |
important data | 3 |
resource shortages | 3 |
current research | 3 |
three sessions | 3 |
icu admission | 3 |
across diverse | 3 |
average efficient | 3 |
participant continues | 3 |
surfactant administration | 3 |
fit among | 3 |
manis pentadactyla | 3 |
vast majority | 3 |
certain diseases | 3 |
record details | 3 |
objectively reasonable | 3 |
intervention arm | 3 |
innovative medicine | 3 |
limited access | 3 |
potent inhibitor | 3 |
will collect | 3 |
previous clinical | 3 |
alone showed | 3 |
single cohort | 3 |
emergency medicine | 3 |
trying times | 3 |
pangolin foraging | 3 |
therapeutic benefit | 3 |
never treated | 3 |
powered multicentre | 3 |
estimated effect | 3 |
nervous system | 3 |
clinical practices | 3 |
guidance documents | 3 |
children across | 3 |
smaller trials | 3 |
trial characteristics | 3 |
significantly impacted | 3 |
medical devices | 3 |
i clinical | 3 |
unrealistic percentages | 3 |
potential health | 3 |
org licenses | 3 |
participants removed | 3 |
registry data | 3 |
children tested | 3 |
tcm formula | 3 |
may limit | 3 |
tract infections | 3 |
uncontrolled trials | 3 |
clinical laboratory | 3 |
exceptional circumstances | 3 |
may conflict | 3 |
one major | 3 |
error learning | 3 |
pharmacologic treatments | 3 |
influenza among | 3 |
based study | 3 |
vs low | 3 |
four control | 3 |
event reporting | 3 |
take advantage | 3 |
top priority | 3 |
prospective clinical | 3 |
across human | 3 |
mass index | 3 |
four elements | 3 |
technological advances | 3 |
weak spot | 3 |
foundation trust | 3 |
concerted efforts | 3 |
pairwise comparisons | 3 |
pradeesh sivapalan | 3 |
media briefing | 3 |
within months | 3 |
data reporting | 3 |
gastric cancer | 3 |
must continue | 3 |
provide written | 3 |
mortality among | 3 |
descriptive study | 3 |
pandemic speed | 3 |
media coverage | 3 |
preventing influenza | 3 |
multicenter trials | 3 |
resveratrol inhibits | 3 |
randomly allocated | 3 |
showed statistically | 3 |
standard approach | 3 |
rich description | 3 |
time interval | 3 |
positive serology | 3 |
demographic data | 3 |
bullous pemphigoid | 3 |
written consent | 3 |
trials indicated | 3 |
trial concept | 3 |
meditation classes | 3 |
children needed | 3 |
includes participants | 3 |
study efficacy | 3 |
missing efficacy | 3 |
data managers | 3 |
secondary outcome | 3 |
comprehensive trial | 3 |
without consent | 3 |
treatment score | 3 |
systematically search | 3 |
high costs | 3 |
methodological issues | 3 |
register unique | 3 |
patient hesitancy | 3 |
adequate sample | 3 |
year follow | 3 |
trial showed | 3 |
hypoxemic respiratory | 3 |
many walls | 3 |
obtaining informed | 3 |
less flexible | 3 |
evaluation will | 3 |
particularly challenging | 3 |
sites per | 3 |
data analyses | 3 |
pandemic setting | 3 |
new zealand | 3 |
report results | 3 |
early due | 3 |
healthy life | 3 |
challenges due | 3 |
collection will | 3 |
tcm granules | 3 |
monitor will | 3 |
empirical investigation | 3 |
first edition | 3 |
greatly impacted | 3 |
provide reassurance | 3 |
antimalarial drug | 3 |
suspected cases | 3 |
public sources | 3 |
glucocorticoid therapy | 3 |
case basis | 3 |
better understand | 3 |
network study | 3 |
will depend | 3 |
pandemic due | 3 |
novel drugs | 3 |
pangolin manis | 3 |
potential future | 3 |
specialist health | 3 |
relevant regulations | 3 |
term follow | 3 |
best interests | 3 |
plague will | 3 |
coordination mechanisms | 3 |
serious side | 3 |
trial adaptations | 3 |
taking part | 3 |
past months | 3 |
rcts assessing | 3 |
trial safety | 3 |
first detected | 3 |
effect sizes | 3 |
well beyond | 3 |
since i | 3 |
potentially eligible | 3 |
consent always | 3 |
different treatment | 3 |
trials must | 3 |
adaptive randomisation | 3 |
start date | 3 |
additional data | 3 |
adult respiratory | 3 |
prevent influenza | 3 |
curve crossed | 3 |
treating clinician | 3 |
diseases outbreaks | 3 |
one per | 3 |
investigative treatments | 3 |
irb approval | 3 |
immunosuppressed patients | 3 |
differences across | 3 |
functional assessment | 3 |
i ii | 3 |
vaccine cvd | 3 |
family members | 3 |
permuted blocks | 3 |
user involvement | 3 |
operational issues | 3 |
either individual | 3 |
trial drug | 3 |
planned sensitivity | 3 |
immunological correlates | 3 |
staff involved | 3 |
grant application | 3 |
selective coding | 3 |
care facilities | 3 |
respiratory virus | 3 |
yet another | 3 |
trials take | 3 |
future study | 3 |
additional challenges | 3 |
trial infrastructure | 3 |
acute hypoxemic | 3 |
second phase | 3 |
patient profile | 3 |
data extraction | 3 |
chemotherapy drugs | 3 |
last authors | 3 |
per country | 3 |
new patients | 3 |
severe dementia | 3 |
plague around | 3 |